Antiretroviral therapy and management of HIV infection

Summary Antiretroviral therapy of HIV infection has changed a uniformly fatal into a potentially chronic disease. There are now 17 drugs in common use for HIV treatment. Patients who can access and adhere to combination therapy should be able to achieve durable, potentially lifelong suppression of H...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 2010-07, Vol.376 (9734), p.49-62
Hauptverfasser: Volberding, Paul A, Prof, Deeks, Steven G, Prof
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 62
container_issue 9734
container_start_page 49
container_title The Lancet (British edition)
container_volume 376
creator Volberding, Paul A, Prof
Deeks, Steven G, Prof
description Summary Antiretroviral therapy of HIV infection has changed a uniformly fatal into a potentially chronic disease. There are now 17 drugs in common use for HIV treatment. Patients who can access and adhere to combination therapy should be able to achieve durable, potentially lifelong suppression of HIV replication. Despite the unquestioned success of antiretroviral therapy, limitations persist. Treatment success needs strict lifelong drug adherence. Although the widely used drugs are generally well tolerated, most have some short-term toxic effects and all have the potential for both known and unknown long-term toxic effects. Drug and administration costs limit treatment in resource-poor regions, and are a growing concern even in resource rich settings. Finally, complete or near complete control of viral replication does not fully restore health. Long-term treated patients who are on an otherwise effective regimen often show persistent immune dysfunction and have higher than expected risk for various non-AIDS-related complications, including heart, bone, liver, kidney, and neurocognitive diseases.
doi_str_mv 10.1016/S0140-6736(10)60676-9
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754567035</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673610606769</els_id><sourcerecordid>754567035</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-406e4a167d49a5697f26b3eb7052f8be2c5661ec09679f22ce878a69fe1939e23</originalsourceid><addsrcrecordid>eNqFkV1rFDEUhoModq3-BGUQRL0YPclMTiY3SinaFgq98APvQjZzoqkzmTWZLey_d2Z3u4Xe9CoQnjw5530Ze8nhAweOH78Br6FEVeE7Du8RUGGpH7EFr1Vdylr9eswWB-SIPcv5GgBqBPmUHQlA0LpRC4YncQyJxjTchGS7YvxDya42hY1t0dtof1NPcSwGX5xf_CxC9OTGMMTn7Im3XaYX-_OY_fj65fvpeXl5dXZxenJZOokwljUg1ZajamttJWrlBS4rWiqQwjdLEhOGnBxoVNoL4ahRjUXtietKk6iO2dudd5WGf2vKo-lDdtR1NtKwzkbJWqKCSj5MVhXKaQQ9ka_vkdfDOsVpDYNQNVpIPevkDnJpyDmRN6sUeps2hoOZCzDbAsyc7ny1LcDM8ld7-XrZU3t4dZv4BLzZAzY72_lkowv5jhO6AQ04cZ93HE3x3gRKJrtA0VE71eVG0w7hwVE-3TO4LsQwffqXNpQPS3OThYGdZHZw2Bp09R9yT7Q5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>603892595</pqid></control><display><type>article</type><title>Antiretroviral therapy and management of HIV infection</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Volberding, Paul A, Prof ; Deeks, Steven G, Prof</creator><creatorcontrib>Volberding, Paul A, Prof ; Deeks, Steven G, Prof</creatorcontrib><description>Summary Antiretroviral therapy of HIV infection has changed a uniformly fatal into a potentially chronic disease. There are now 17 drugs in common use for HIV treatment. Patients who can access and adhere to combination therapy should be able to achieve durable, potentially lifelong suppression of HIV replication. Despite the unquestioned success of antiretroviral therapy, limitations persist. Treatment success needs strict lifelong drug adherence. Although the widely used drugs are generally well tolerated, most have some short-term toxic effects and all have the potential for both known and unknown long-term toxic effects. Drug and administration costs limit treatment in resource-poor regions, and are a growing concern even in resource rich settings. Finally, complete or near complete control of viral replication does not fully restore health. Long-term treated patients who are on an otherwise effective regimen often show persistent immune dysfunction and have higher than expected risk for various non-AIDS-related complications, including heart, bone, liver, kidney, and neurocognitive diseases.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(10)60676-9</identifier><identifier>PMID: 20609987</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Acquired immune deficiency syndrome ; AIDS ; Anti-Retroviral Agents - adverse effects ; Anti-Retroviral Agents - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral agents ; Antiretroviral drugs ; Antiviral agents ; Biological and medical sciences ; Bone ; Clinical medicine ; Drug Resistance, Viral ; Epidemiology ; Family medical history ; General aspects ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV Infections - physiopathology ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Internal Medicine ; Medical sciences ; Mortality ; Pathogenesis ; Pharmacology. Drug treatments ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>The Lancet (British edition), 2010-07, Vol.376 (9734), p.49-62</ispartof><rights>Elsevier Ltd</rights><rights>2010 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2010 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jul 3-Jul 9, 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-406e4a167d49a5697f26b3eb7052f8be2c5661ec09679f22ce878a69fe1939e23</citedby><cites>FETCH-LOGICAL-c560t-406e4a167d49a5697f26b3eb7052f8be2c5661ec09679f22ce878a69fe1939e23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/603892595?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22980906$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20609987$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Volberding, Paul A, Prof</creatorcontrib><creatorcontrib>Deeks, Steven G, Prof</creatorcontrib><title>Antiretroviral therapy and management of HIV infection</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Summary Antiretroviral therapy of HIV infection has changed a uniformly fatal into a potentially chronic disease. There are now 17 drugs in common use for HIV treatment. Patients who can access and adhere to combination therapy should be able to achieve durable, potentially lifelong suppression of HIV replication. Despite the unquestioned success of antiretroviral therapy, limitations persist. Treatment success needs strict lifelong drug adherence. Although the widely used drugs are generally well tolerated, most have some short-term toxic effects and all have the potential for both known and unknown long-term toxic effects. Drug and administration costs limit treatment in resource-poor regions, and are a growing concern even in resource rich settings. Finally, complete or near complete control of viral replication does not fully restore health. Long-term treated patients who are on an otherwise effective regimen often show persistent immune dysfunction and have higher than expected risk for various non-AIDS-related complications, including heart, bone, liver, kidney, and neurocognitive diseases.</description><subject>Acquired immune deficiency syndrome</subject><subject>AIDS</subject><subject>Anti-Retroviral Agents - adverse effects</subject><subject>Anti-Retroviral Agents - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Bone</subject><subject>Clinical medicine</subject><subject>Drug Resistance, Viral</subject><subject>Epidemiology</subject><subject>Family medical history</subject><subject>General aspects</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - physiopathology</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Internal Medicine</subject><subject>Medical sciences</subject><subject>Mortality</subject><subject>Pathogenesis</subject><subject>Pharmacology. Drug treatments</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkV1rFDEUhoModq3-BGUQRL0YPclMTiY3SinaFgq98APvQjZzoqkzmTWZLey_d2Z3u4Xe9CoQnjw5530Ze8nhAweOH78Br6FEVeE7Du8RUGGpH7EFr1Vdylr9eswWB-SIPcv5GgBqBPmUHQlA0LpRC4YncQyJxjTchGS7YvxDya42hY1t0dtof1NPcSwGX5xf_CxC9OTGMMTn7Im3XaYX-_OY_fj65fvpeXl5dXZxenJZOokwljUg1ZajamttJWrlBS4rWiqQwjdLEhOGnBxoVNoL4ahRjUXtietKk6iO2dudd5WGf2vKo-lDdtR1NtKwzkbJWqKCSj5MVhXKaQQ9ka_vkdfDOsVpDYNQNVpIPevkDnJpyDmRN6sUeps2hoOZCzDbAsyc7ny1LcDM8ld7-XrZU3t4dZv4BLzZAzY72_lkowv5jhO6AQ04cZ93HE3x3gRKJrtA0VE71eVG0w7hwVE-3TO4LsQwffqXNpQPS3OThYGdZHZw2Bp09R9yT7Q5</recordid><startdate>20100703</startdate><enddate>20100703</enddate><creator>Volberding, Paul A, Prof</creator><creator>Deeks, Steven G, Prof</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>7T5</scope><scope>7U1</scope><scope>7U2</scope></search><sort><creationdate>20100703</creationdate><title>Antiretroviral therapy and management of HIV infection</title><author>Volberding, Paul A, Prof ; Deeks, Steven G, Prof</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-406e4a167d49a5697f26b3eb7052f8be2c5661ec09679f22ce878a69fe1939e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>AIDS</topic><topic>Anti-Retroviral Agents - adverse effects</topic><topic>Anti-Retroviral Agents - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Bone</topic><topic>Clinical medicine</topic><topic>Drug Resistance, Viral</topic><topic>Epidemiology</topic><topic>Family medical history</topic><topic>General aspects</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - physiopathology</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Internal Medicine</topic><topic>Medical sciences</topic><topic>Mortality</topic><topic>Pathogenesis</topic><topic>Pharmacology. Drug treatments</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Volberding, Paul A, Prof</creatorcontrib><creatorcontrib>Deeks, Steven G, Prof</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Volberding, Paul A, Prof</au><au>Deeks, Steven G, Prof</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiretroviral therapy and management of HIV infection</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2010-07-03</date><risdate>2010</risdate><volume>376</volume><issue>9734</issue><spage>49</spage><epage>62</epage><pages>49-62</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Summary Antiretroviral therapy of HIV infection has changed a uniformly fatal into a potentially chronic disease. There are now 17 drugs in common use for HIV treatment. Patients who can access and adhere to combination therapy should be able to achieve durable, potentially lifelong suppression of HIV replication. Despite the unquestioned success of antiretroviral therapy, limitations persist. Treatment success needs strict lifelong drug adherence. Although the widely used drugs are generally well tolerated, most have some short-term toxic effects and all have the potential for both known and unknown long-term toxic effects. Drug and administration costs limit treatment in resource-poor regions, and are a growing concern even in resource rich settings. Finally, complete or near complete control of viral replication does not fully restore health. Long-term treated patients who are on an otherwise effective regimen often show persistent immune dysfunction and have higher than expected risk for various non-AIDS-related complications, including heart, bone, liver, kidney, and neurocognitive diseases.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>20609987</pmid><doi>10.1016/S0140-6736(10)60676-9</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0140-6736
ispartof The Lancet (British edition), 2010-07, Vol.376 (9734), p.49-62
issn 0140-6736
1474-547X
language eng
recordid cdi_proquest_miscellaneous_754567035
source MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland
subjects Acquired immune deficiency syndrome
AIDS
Anti-Retroviral Agents - adverse effects
Anti-Retroviral Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretroviral agents
Antiretroviral drugs
Antiviral agents
Biological and medical sciences
Bone
Clinical medicine
Drug Resistance, Viral
Epidemiology
Family medical history
General aspects
HIV
HIV Infections - complications
HIV Infections - drug therapy
HIV Infections - physiopathology
Human immunodeficiency virus
Human viral diseases
Humans
Infectious diseases
Internal Medicine
Medical sciences
Mortality
Pathogenesis
Pharmacology. Drug treatments
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
title Antiretroviral therapy and management of HIV infection
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T20%3A39%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiretroviral%20therapy%20and%20management%20of%20HIV%20infection&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Volberding,%20Paul%20A,%20Prof&rft.date=2010-07-03&rft.volume=376&rft.issue=9734&rft.spage=49&rft.epage=62&rft.pages=49-62&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(10)60676-9&rft_dat=%3Cproquest_cross%3E754567035%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=603892595&rft_id=info:pmid/20609987&rft_els_id=S0140673610606769&rfr_iscdi=true